Jump Financial LLC Purchases Shares of 1,046 United Therapeutics Co. (NASDAQ:UTHR)

Jump Financial LLC purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,046 shares of the biotechnology company's stock, valued at approximately $369,000.

Other institutional investors have also made changes to their positions in the company. Parallel Advisors LLC increased its stake in shares of United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after buying an additional 30 shares during the period. Signaturefd LLC increased its stake in shares of United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC grew its stake in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC grew its stake in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after purchasing an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its stake in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after purchasing an additional 33 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 74,500 shares of company stock valued at $24,472,050. 11.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on UTHR shares. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research note on Friday. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. JPMorgan Chase & Co. reduced their target price on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Finally, Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a report on Monday, April 21st. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $390.17.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $5.66 during trading hours on Monday, hitting $297.04. 410,281 shares of the company traded hands, compared to its average volume of 447,897. The stock has a market capitalization of $13.34 billion, a price-to-earnings ratio of 13.05, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a twelve month low of $233.31 and a twelve month high of $417.82. The business's 50-day moving average is $307.00 and its 200-day moving average is $346.00.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. During the same period last year, the business earned $4.36 earnings per share. Analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.